Hariprasad Vankayalapati, PhD, M Pharm

Research Interests

  • Drug Discovery
  • Medicinal Chemistry
  • Computational Sciences
  • Organic Synthesis
  • Kinase Inhibitors
  • Small Molecule Targeted Drug Discovery
  • Design and Synthesis of Targeted Cancer Drugs
  • Epigenetics in Cancer
  • Ewing's Sarcoma
  • Autoimmune Diseases
  • Neurodegenerative Diseases
  • Transcription Factors
  • Drug Metabolism & Pharmacokinetics
  • Pharmacokinetics

Languages

  • English
  • Hindi
  • Telugu

Academic Information

  • Departments: Medicinal Chemistry - Research Associate Professor

Academic Office Information

  • 801-213-8424
  • Huntsman Cancer Institute
    Huntsman Cancer Institute's Center for Investigational Therapeutics
    2000 Circle of Hope, Room: 3264
    Salt Lake City, UT 84112

Academic Bio

Hariprasad Vankayalapati, M.Pharm., Ph.D.

Assistant Professor of Medicinal Chemistry

Hariprasad Vankayalapati, Ph.D., is an Associate Prof. of Medicinal Chemistry and investigator at Center for Investigational Therapeutics of Huntsman Cancer Institute (HCI) and College of Pharmacy of University of Utah. Dr. Hari is supporting drug discovery programs under accelerator therapeutics initiative at the center.

Dr. Hari was serving as Associate Professor of Medicinal Chemistry at the Applied Cancer Research and Drug Discovery Division of Translational Genomics Research Institute (TGen) of City Of Hope in Phoenix, AZ from Oct 2017 to March 2019. His research focuses on early discovery, and to IND stage of development of small molecule targeted therapeutics particularly; targeting kinase signaling, immunokinases, epigenetics, nuclear hormone receptors, and immune therapeutics - A target class in treating cancer, inflammation, and autoimmune, diseases.

Prior to TGen, Dr. Hari was serving as Assistant Professor/Chief Scientist of Medicinal Chemistry at the Center for Investigational Therapeutics (CIT) of The Huntsman Cancer Institute (HCI) & School of Medicine of University Of Utah in Salt Lake City (Nov 2009 to Sep 2017). With a support from Huntsman Cancer Institute, Dr. Hari established a Medicinal, Organic, Computational Chemistry capabilities and successfully executed the translational research in search for novel cancer therapeutics. His researches at HCI lead to two spin-off Pharmaceutical companies and clinical stage agents two entered in to Phase 1 trials (SP-2577, HCI-2084/TP-0903). From 2006-2009 Dr. Hari served as Director and Chief Scientist at the SuperGen/Astex Pharmaceuticals (now Otsuka Pharmaceuticals). From 2003-2006 he was serving as program director of Medicinal Chemistry for early discovery, development and was key in creating several pipeline pre-clinical programs, CLIMB technology and co-founded Montigen Pharmaceuticals in year 2003. Later in year 2006 Montigen was acquired by SuperGen Inc., for 40 million where Dr. Hari played a key role in bringing science/technology in this deal transaction. Dr. Hari’s involvement over the years in Drug Discovery/Development, and his leadership in Pharma/Biotech industry lead to the discovery of first-in-class three clinical phase drug candidates; Amuvatinib/MP-470, SGI-1776 and SGI-110/Guadecitabine.

In addition, Dr. Hari is also serving as Chief Scientific Officer of Arrien Pharmaceuticals where he successfully discovered ARN-6039, completed Phase 1 safety trials and partnered to pharma now moved in to Phase 2 trials (ARN-6039/BOS-172767) for autoimmune/psoriasis disease treatment. In addition, Dr. Hari currently is developing an ovarian cancer agent ARN-3261, regulatory approvals completed to clinical Phase 1 to begin in Q3 2019. Dr. Hari is also serving as scientific advisor for few Pharmaceutical companies.

He is an author of more than 70 peer reviewed scientific publications & presentations in Medicinal, Organic, Computational Chemistry and drug discovery areas. He is an inventor of over 23 published/issued US/WO patents. He holds Ph.D., and M. Pharm degrees in Medicinal Chemistry from the Institute of Chemical Technology (formally UDCT) of University of Mumbai and University of Karnatak in India. He completed his Post-Doctoral training in Organic Chemistry from University of Sunderland in England and Medicinal Chemistry from University of Arizona Cancer Center in Tucson, AZ, USA.

Education History

Type School Degree
Postdoctoral Fellowship Arizona Cancer Center, University of Arizona Health Sciences Center
Medicinal Chemistry
Senior Postdoctoral Fellow
Postdoctoral Fellowship University of Sunderland, School of Health Sciences
Organic Chemistry
Postdoctoral Fellow
Doctoral Training Institute of Chemical Technology (ICT, Formally UDCT), University of Bombay
Medicinal Chemistry
Ph.D.
Graduate Training K.L.E’s College of Pharmacy, Karnataka University
Pharmaceutical Chemistry
M.S.
Undergraduate H.K.E’s College of Pharmacy, Gulbarga University, Gulbarga
Pharmaceutical Sciences
B.S.

Global Impact

Education History

Type School Degree Country
Postdoctoral Fellowship University of Sunderland, School of Health Sciences
Organic Chemistry
Postdoctoral Fellow United Kingdom
Doctoral Training Institute of Chemical Technology (ICT, Formally UDCT), University of Bombay
Medicinal Chemistry
Ph.D. India
Graduate Training K.L.E’s College of Pharmacy, Karnataka University
Pharmaceutical Chemistry
M.S. India
Undergraduate H.K.E’s College of Pharmacy, Gulbarga University, Gulbarga
Pharmaceutical Sciences
B.S. India

Selected Publications

Patent

  1. Vankayalapati H, Liu X, Sharma S, Kasibhatla S, Reddy SV (2017). Preparation of novel prodrugs of anthracene-9,10-dione dioxime compounds and their use as antitumor agents. PCT Int. Appl. U.S. Patent No. WO 2017019875 A1 20170202. Washington, D.C.:U.S. Patent and Trademark Office.
  2. Vankayalapati H, Sharma S, Liu X, Coburn C (2017). Substituted benzohydrazide analogs as histone demethylase inhibitors. PCT Int. Appl. U.S. Patent No. WO 2017019875 A1 20170202. Washington, D.C.:U.S. Patent and Trademark Office.
  3. Vankayalapati H, Sorna V, Warner SL, Bearss DJ, Sharma S (2016). Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors. U.S. Patent No. US 9296703 B2 20160329. Washington, D.C.:U.S. Patent and Trademark Office.
  4. Vankayalapati H, Sorna V, Warner SL, Bearss DJ, Sharma S (2015). Substituted n-(3-pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors. U.S. Pat. Appl. Publ. U.S. Patent No. US 20150252048 A1 20150910. Washington, D.C.:U.S. Patent and Trademark Office.
  5. Ostanin K, Shenderovich M, Bajji A, Cioffi CL, Moss N, Vankayalapati H, Li D (2015). ARF6 inhibitors and methods of synthesis and use thereof. PCT Int. Appl. U.S. Patent No. WO 2015183989 A1 20151203. Washington, D.C.:U.S. Patent and Trademark Office.
  6. Vankayalapati H, Yerramreddy V, Gangireddy P, Appalaneni RP (2014). Preparation of 3,5-(un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine as dual ITK and JAK3 kinase inhibitors. U.S. Pat. Appl. Publ. U.S. Patent No. US 20140315909 A1. Washington, D.C.:U.S. Patent and Trademark Office.
  7. Vankayalapati H, Yerramreddy V, Gangireddy P, Appalaneni RP (2014). Preparation of 3,5-(un)substituted-1H-pyrrolo[2,3-b]pyridine, 1H-pyrazolo[3,4-b]pyridine and 5H-pyrrolo[2,3-b]pyrazine as dual ITK and JAK3 kinase inhibitors. PCT Int. Appl. U.S. Patent No. WO 2014172513 A. Washington, D.C.:U.S. Patent and Trademark Office.
  8. Vankayalapati H, Yoshioka M, Strovel JW, Padia JK (2014). Methods and compositions for inhibition of bromodomain-containing proteins. U.S. Patent No. WO 2014159837 A1. Washington, D.C.:U.S. Patent and Trademark Office.
  9. Vankayalapati H, Venkataswamy S, Warner SL, David DJ, Sharma S (2014). Preparation of substituted (E)-N'-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors. U.S. Patent No. WO 2014055928 A2. Washington, D.C.:U.S. Patent and Trademark Office.
  10. Vankayalapati H, Yerramreddy VK, Ganipisetty V, Talluri S, Rajendra PA (2014). Preparation of substituted 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors. U.S. Patent No. WO 2014093383 A1. Washington, D.C.:U.S. Patent and Trademark Office.
  11. Vankayalapati H, Yerramreddy VK, Ganipisetty V, Talluri S, Rajendra PA (2014). Preparation of substituted 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors. U.S. Patent No. 20140256704 A1. Washington, D.C.:U.S. Patent and Trademark Office.
  12. Alexis M, Steven SL, Gary AF, Vankayalapati H, David DJ (2014). Jak2 and alk2 inhibitors and methods for their use. U.S. Patent No. WO 2014151871 A2. Washington, D.C.:U.S. Patent and Trademark Office.
  13. Vankayalapati H, Sorna V, Warner SL, Bearss DJ, Sharma S (2014). Preparation of substituted N-(3-(pyrimidin-4-l)phenyl)acrylamide analogs as tyrosine receptor kinase Btk inhibitors. PCT Int. Appl. U.S. Patent No. WO 2014055928 A2. Washington, D.C.:U.S. Patent and Trademark Office.
  14. Vankayalapati H, Sorna V, Warner SL, Bearss DJ, Sharma S, Stephens B. (2013). Substituted (E)-N'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors. U.S. Patent No. WO 2013025805 A1. Washington, D.C.:U.S. Patent and Trademark Office.
  15. Vankayalapati H, Appalaneni RP, Reddy YVK. (2012). Preparation of substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3,4-b]pyridine and pyrazolo [3,4-b]pyridine derivatives as protein kinase inhibitors. PCT Int. Appl. U.S. Patent No. WO 2012135631 A1. Washington, D.C.:U.S. Patent and Trademark Office.
  16. Bearss DJ, Vankayalapati H, Mollard A, Warner SL, Sharma S. (2012). Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase. PCT Int. Appl. U.S. Patent No. WO 2012135800 A1. Washington, D.C.:U.S. Patent and Trademark Office.
  17. Bearss DJ, Vankayalapati H, Sorna V, Warner SL, Sharma S. (2012). Preparation of substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors. PCT Int. Appl. (2012). U.S. Patent No. WO 2012135801 A1. Washington, D.C.:U.S. Patent and Trademark Office.
  18. Bearss DJ, Vankayalapati H, Sorna V, Warner SL, Sharma S. (2012). Preparation of substituted 3-(1H-benzo[d]imidazol-2-yl)-1H-indazole analogs as inhibitors of the PDK1 kinase for treating proliferative disorders. PCT Int. Appl. (2012). U.S. Patent No. WO 2012135799 A1. Washington, D.C.:U.S. Patent and Trademark Office.
  19. Vankayalapati H, Swierczek K, Pearce SA. (2010). Cycloalkathiophene derivatives as DNA methyltransferase inhibitors and their preparation and use for the treatment of cancer and hyperproliferative diseases. PCT Int. Appl. (2010). U.S. Patent No. WO 2010098866 A1. Washington, D.C.:U.S. Patent and Trademark Office.
  20. Vankayalapati H, Liu X, Hewitt W, Gurley E, Xu Yong S, Avula B. (2010). Preparation of pyrrolopyrimidine derivatives and analogs for use as AXL kinase inhibitors. PCT Int. Appl. (2010). U.S. Patent No. WO 2010090764.. Washington, D.C.:U.S. Patent and Trademark Office.
  21. Bearss DJ, Vankayalapati H, Xu Y, Fischetti VA, Stebbins C (2009). Preparation of oxo-imidazolyl compounds having antibacterial activity. PCT Int. Appl. (2009). U.S. Patent No. WO 2009139870 A1. Washington, D.C.:U.S. Patent and Trademark Office.
  22. Hurley LH, Mahadevan D, Han H, Bearss DJ, Vankayalapati H, Bashyam S, Warner SL (2008). Substituted Tricyclic Compounds as Protein Kinase Inhibitors. US. Appl., 180pp. US 7,326,713 B2. Granted Patent.
  23. Hurley LH, Mahadevan D, Han H, Bearss DJ, Vankayalapati H, Bashyam S, Warner SL (2008). Substituted Tricyclic Compounds as Protein Kinase Inhibitors. US. Appl. (2008), 188pp. US 7,326,712 B2. Granted Patent.
  24. Phiasivongsa P, Redkar S, Gamage S, Brooke D, Denny W, Bearss DJ, Vankayalapati H (2008). Quinoline derivatives for modulating DNA methylation and their preparation and use in the treatment of cancer and hematological disorders. PCT Int. Appl., 169pp. WO 2008046085.
  25. Bearss DJ, Vankayalapati H, Xu Y (2008). Preparation of substituted pyrrolopyrimidine derivatives and analogs as Axl kinase inhibitors. PCT Int. Appl., 53pp. U.S. Patent No. WO 2008128072.. Washington, D.C.:U.S. Patent and Trademark Office.
  26. Hurley LH, Mahadevan D, Han H, Bearss DJ, Vankayalapati H, Bashyam S, Warner SL (2008). Substituted Tricyclic Compounds as Protein Kinase Inhibitors. US. Appl., 188pp. US 7,335,662 B2. Granted Patent.
  27. Bearss DJ, Grand CL, Liu XH, Vankayalapati H (2008). Piperazinyl pyrimido-indole derivatives as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. PCT Int. Appl., 111pp. WO 2008055233.
  28. Bearss DJ, Liu XH, Vankayalapati H, Xu Y (2008). Preparation of imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives as protein kinase inhibitors. PCT Int. Appl., 107 pp. WO 2008058126.
  29. Bearss DJ, Joshi-Hangal R, Liu, XH, Phiasivongsa PR, Sanjeev G, Vankayalapati H (2008). Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same. U.S. Pat. Appl. Publ., 32pp. US 2008226747.
  30. Hurley L H, Mahadevan D, Han H, Bearss DJ, Vankayalapati H, Bashyam S, Munoz RM, Warner SL, Della Croce K, Von Hoff DD, Grand CL, Welsh J (2008). Preparation of fused pyrimidines as therapeutic protein kinase inhibitors. U.S. Pat. Appl. Publ., 137pp. US 2008051414.
  31. Vankayalapati H, Liu XH, Bearss DJ (2008). Pyrimidine-2,4-diamine derivatives as JAK2 kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. PCT Int. Appl., 65pp. WO 2008106635.
  32. Hurley LH, Mahadevan D, Han H, Bearss DJ, Vankayalapati H, Bashyam S, Warner SL (2007). Substituted Tricyclic Compounds as Protein Kinase Inhibitors. US. Appl., 128pp. US 7,312,226 B2. Granted Patent.
  33. Bearss DJ, Xiao-Hu L, Vankayalapati H, Yong Xu (2007). Imidazo[1,2-b]Pyridazine and Pyrazolo[1,5-a]Ppyrmidine derivatives and their use as Protein Kinase Inhibitors. PCT Int. Appl., (Supergen, Inc., USA). U.S. Patent No. US 2007083773.. Washington, D.C.:U.S. Patent and Trademark Office.
  34. Bearss DJ, Vankayalapati H, Grand CL (2006). Preparation of pyrimidoindolylpiperazines as protein kinase inhibitors. PCT Int. Appl., 59pp.(Supergen, Inc., USA). U.S. Patent No. WO 2006116733. Washington, D.C.:U.S. Patent and Trademark Office.
  35. Bearss DJ, Vankayalapati H, Grand CL (2006). Preparation of cinnolines and related compounds as inhibitors of polo-like kinase-1 (Plk-1). PCT Int. Appl., 46pp. WO 2006124996.
  36. Laurence LH, Mahadevan D, Han H, Bearss DJ, Vankayalapati H, Bashyam S, Munoz RM, Warner SL, Della C, Von Hoff DD, Grand CL (2005). Preparation of fused pyrimidines as protein kinase inhibitors PCT Int. Appl., 170 pp. WO2005037825. (Arizona Arizona Board of Regents on Behalf of the University, USA; Montigen Pharmaceuticals, Inc.). U.S. Patent No. WO2005037825. Washington, D.C.:U.S. Patent and Trademark Office.
  37. Farnsworth AL, Han H, Vankayalapati H, Warner S, Von Hoff DD, Bearss DJ (2004). Targeting protein tyrosine phosphatase PRL-1 for the treatment of pancreatic cancer. PCT Int. Appl., 118 pp. WO 2004079012.
  38. Vankayalapati H, Talele TT, Kulkarni VM (1997). Substituted alkenoyl 4-hydroxycoumarins as HIV-1 protease inhibitors: Patent No:182397 (Application No.369/Bom/96 dated 15-7-1997).
  39. Vankayalapati H, Talele TT, Kulkarni VM (1996). 2-Substituted-3-hydroxy-4-oxo-4H-1-benzopyrans as HIV-1 protease inhibitors: Patent No: awaiting (Application No:368/Bom/96 dated 15-7-1996).